Paper Details

  1. Home
  2. Paper Details

Nanomicelle formulation modifies the pharmacokinetic profiles and cardiac toxicity of daunorubicin.

Author: ChenMingyi, HaddadAshraf S, HendersonPaul T, JonasBrian A, LamKit S, LiYuanpei, LinTzu-Yin, LiuRuiwu, PanChong-xian, XiaoKai, XiaoWenwu, ZhangHongyong

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Overview

Leukemia stem cell-targeting micelles dramatically change the pharmacokinetics and reduce the cardiac toxicity of daunorubicin (DNR).
Paper Details　
Original Abstract of the Article :
BACKGROUND: Treatment with daunorubicin (DNR) in acute myeloid leukemia is moderately effective and associated with significant side effects, including cardiac toxicity. We recently developed a nanomicellar formulation of DNR that specifically targets acute myeloid leukemia stem cells. MATERIALS & ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/24628688

データ提供：米国国立医学図書館（NLM）

A Nanomicellar Approach to Daunorubicin Delivery

[Daunorubicin (DNR)] is a chemotherapy drug used in the treatment of acute myeloid leukemia. However, it can cause significant side effects, particularly [cardiac toxicity]. This research investigated the potential of a [nanomicellar formulation] of DNR to modify its pharmacokinetic profile and reduce cardiac toxicity. The researchers found that the nanomicellar formulation of DNR significantly increased its drug concentration in the target tissue and reduced cardiac toxicity in both mice and rats, compared to free DNR. This suggests that the nanomicellar formulation may be a more effective and safer delivery system for DNR.

A Smarter Approach to Drug Delivery

The study suggests that nanomicellar formulation of DNR could be a safer and more effective treatment option for acute myeloid leukemia. This approach could minimize the side effects of DNR while maximizing its therapeutic benefits.

Navigating the Desert of Chemotherapy

This research provides hope for those navigating the harsh landscape of chemotherapy. By finding innovative ways to deliver drugs, we can strive to reduce the toxic effects and improve the efficacy of treatment, ultimately giving patients a better chance of overcoming cancer.

Dr.Camel's Conclusion

This research, like a clever camel finding a hidden oasis, reveals the potential of nanomicellar formulation to improve the delivery of chemotherapy drugs. It offers a glimmer of hope for those battling cancer, suggesting a path towards safer and more effective treatment.

Date :
  1. Date Completed 2015-06-22
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

24628688

DOI: Digital Object Identifier

NIHMS617971

Related Literature

Article Analysis
・Side Effects of daunorubicin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.